TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* all races and ethnicities~* bipolar disorder I or II~* currently treated with lithium, divalproex, lamotrigine, and/or second generation antipsychotic~* doses stable for greater than or equal to 4 weeks~* current CGI BP score of moderate or greater~* current CDRS-R severity of greater than or equal to 35~Exclusion Criteria:~* If female, pregnant or sexually active without reliable contraception~* significant suicidal ideations (as determined by clinical interview or CDRS-R \> 3) and/or any suicidal intent, even if fleeting or non-recurrent, in the preceding 2 weeks~* substance dependence within the past 2 months~* daily antidepressant, glucocorticoid, nonsteroidal anti-inflammatory, anti-platelet, anti-coagulant, antacid, or oral hypoglycemic medication or insulin; high-dose antioxidant vitamin supplements or other natural health products that may function as an antidepressant within 30 days of baseline~* IQ\<80 or autistic disorder~* full threshold mania and/or YMRS \> 20 and/or psychosis~* hypersensitivity to curcumin/turmeric, gelatin~* dietary consumption of curcumin/turmeric \> 3 times/week~* clinically significant or unstable medical disorder; known gallstones and/or bile duct obstruction, stomach ulcers, excessive stomach acid/heartburn/gastroesophageal reflux disease (GERD); or clinically significant baseline laboratory abnormalities; or ALT and /or AST above the upper limit of normal on repeat examination at baseline~* severe depression (CDRS-R \> 98) and/or severely ill (CGI BP \>5)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- adjunctive curcumin (Type: EXPERIMENTAL): Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18 years.~* Performance status ≤ 2 according to the WHO criteria.~* Life expectancy\> 3 months.~* Patient in hormonal blockade based on surgical castration by orchiectomy or pulpectomy, medical or agonist or antagonists of LHRH associated or not with anti-androgens or any other treatment that blocks the fraction of non-gonadal testosterone, resulting in a testosterone \<0.5 ng / mL.~* Patient with adenocarcinoma of the prostate and histologically proven metastatic castration-resistant stage, defined by: objective progression of at least one measurable tumor target and / or assessable by RECIST, and / or increase in PSA (rising PSA).~* Satisfactory biological functions (renal, hepatic and hematologic)~* Patient who signed the consent for participation before entering the study.~* Affiliation to a social security scheme (or be the beneficiary of such a plan) under the terms of the law of 9 August 2004.~Exclusion Criteria:~* Age \<18 years.~* Performance status\> 2 according to the WHO criteria.~* Patient deprived of liberty or under guardianship, patient with (the) condition (s) psychological, family, social or geographic may interfere with the proper conduct of the study.~* Diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer considered cured.~* Patient with brain metastases at initial assessment.~* Patient with another pathology deemed incompatible with the inclusion in the protocol.~* Laboratory tests inadequate.~* History of malabsorption syndrome or extensive resection of the upper digestive tract.~* Uncontrolled intercurrent infection.~* Pathology autoimmune and / or chronic active inflammation.~* peripheral neuropathy grade 2 according to the criteria of the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE, version 4.0).~* History of allergy to polysorbate 80.~* Treatment with nonsteroidal anti-inflammatory and / or cyclooxygenase-2 dated within three weeks.~* Concomitant with a drug test or participation in another clinical trial within \<30 days treatment.~* Regular Taking dietary supplements.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Curcumin (Type: EXPERIMENTAL): curcumine capsule
- Placebo (Type: PLACEBO_COMPARATOR): placebo capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Retrospective Assessment of the Morphology of Acetabular Defects: A 3D Reconstruction Approach

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Trainings dataset for statistical shape model:~* Patients where a bilateral CT of the hip was performed with unilateral pathologies.~* We aim to include an equal amount of scans from each gender and varying ages.~Dataset of defect acetabula used for reconstruction:~* Patients who received a CT scan of the hip after removal of a primary/revision implant (e.g. patients where debridement was performed due to infection.)~* Patients where the defect can be classified as a Paprosky 3a or 3b defect.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy hip population (Type: None): None
- Hip defect population (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Novel Quantitative MRI for Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Active AS meeting the modified New York criteria~* BASDAI ≥ 4~* Elevated C-Reactive Protein~* ≥ 18 years old~* Initiation of TNFi treatment with CZP~Exclusion Criteria:~* Previous treatment with more than one biologics~* Biologic treatment within six-months (no more than 20% of group (n=4) for patients with previous biologic treatment)~* Non-response to previous anti TNF treatment~* Fibromyalgia or other reasons for back pain~* Pregnant patients~* Patients on \> 10mg of Prednisone per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cases - Ankylosing Spondylitis Cohort (Type: None): 20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
- Controls - w/o Ankylosing Spondylitis (Type: None): 5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EndoStim Patient Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject meets therapy indications~2. Subject signs informed consent~3. Subject has a planned EndoStim LES Stimulation System implant (prospective) OR subject has already had EndoStim LES Stimulation System implant (retrospective)~Exclusion Criteria:~1. Subject meets therapy contraindications

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EndoStim LES Stimulation System implant. (Type: None): Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Atelectasis Formation with Electrical Impedance Tomography During Anesthesia for MRI in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status 1 to 3,~* 1 to 6 years of age with legal guardians providing written informed consent.~Exclusion Criteria:~* Exclusion criteria are necessity to intubate the child,~* contraindication for propofol administration,~* congenital heart or lung disease with oxygen~* dependency and high aspiration risk (requiring rapid sequence induction intubation).

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Consultations Reason for Genital, Urinary or Psychological Humans in General Practice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male patients overbetween 18 and 80 years old and~* Patients consulting for a sexual, urogenital or psychological reason according to Interntational Classification of Primary Care (ICPC-2) will be included.~Exclusion Criteria:~* Patients consulting for Aanother reason for visiting thethan urogenital pattern, sexual or psychological~* Nonunderstanding of the French language~* Patients with psychiatric disorders affecting judgement~* Patient refusal to participate in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Interventional GP : GP trainned in communication skills (Type: OTHER): The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize).
- Usual care : GP did not trainnd in communication skills (Type: OTHER): The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced or recurrent breast cancer~* Resistant against anthracycline-based and taxane-based chemotherapy or difficult to continue the chemotherapy due to intolerable side effect(s)~* Resistant against trastuzumab or difficult to continue it due to intolerable side effect(s) when her-2 is positive~* ECOG performance status 0-2~* Life expectancy \> 3 months~* HLA-A\*0201~* Laboratory values as follows~  * 2000/mm3\<WBC\<15000/mm3~ * Platelet count\>100000/mm3~ * Bilirubin \< 3.0mg/dl~ * Asparate transaminase \< 150IU/L~ * Alanine transaminase \< 150IU/L~ * Creatinine \< 3.0mg/dl~* Able and willing to give valid written informed consent~Exclusion Criteria:~* Pregnancy(woman of childbearing potential:Refusal or inability to use effective means of contraception)~* Breastfeeding~* Active or uncontrolled infection~* Unhealed external wound~* Concurrent treatment with steroids or immunosuppressing agent~* Prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks~* Uncontrolled brain and/or intraspinal lesion(s)~* Decision of unsuitableness by principal investigator or physician-in-charge

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Peptide administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed biopsy proven prostate carcinoma who are referred to Diagnostic Imaging for magnetic resonance imaging (MRI) / magnetic resonance spectroscopic imaging (MRSI)~2. No previous radiation to prostate or pelvis~3. No hormonal treatment for prostate~4. The interval between the biopsy and magnetic resonance spectroscopic imaging (MRSI): more than 6 weeks~5. Informed consent~Exclusion Criteria:~1. Contraindications for MRI (e.g. cardiac pacemaker)~2. Allergy to Latex~3. Contraindications for magnetic resonance spectroscopic imaging (MRSI) (e.g. history of abdomino-perineal resection of rectum)~4. Metals or any conditions (e.g. hip prosthesis) that can distort the local magnetic field~5. Previous prostate surgery for prostate carcinoma (including, transurethral resection of the prostate (TURP) and cryosurgery), local or systemic treatment for prostate carcinoma (e.g. radiation, androgen deprivation), pelvic radiation (e.g. rectal cancer), rectal surgery, BCG for bladder cancer~6. Children (\<18 years)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIR-MRSI (Type: EXPERIMENTAL): Endorectal MRSI with Air
- PFC-MRSI (Type: EXPERIMENTAL): Endorectal MRSI with PFC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV viral load \> 1,000 on current antiviral medications~* No resistance to study medications~* Over 18 years of age~Exclusion Criteria:~* Hepatitis B co-infection~* Pregnancy~* Previous therapy with either of the study medications~* Ongoing substance abuse~* Significant history of other physical disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid (Type: OTHER): single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Stent Selection for the Femoropopliteal Artery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects eligible for participating in this study are patients with severe PAD who have:~  1. endovascular repair of their femoropopliteal artery~ 2. standard pre-operative contrast-enhanced thin-section CTA of the lower extremities~ 3. intraoperative angiograms and blood pressure measurements proximal and distal to the stent during the endovascular repair~ 4. no aneurysmal disease of the target femoropopliteal artery~ 5. no prior open or endovascular repair of the target femoropopliteal artery (patients with re-interventions are not eligible)~ 6. at least 2 out of 3 patent crural outflow vessels~ 7. life expectancy \>6 months~ 8. no iodinated contrast allergy~ 9. creatinine less than 1.6 g/dL (unless on chronic dialysis, dialysis patients are eligible)~ 10. no orthopedic prostheses in the region of interest~ 11. ability to comply with 6-12-month follow-up contrast enhanced thin-section CTA~Exclusion Criteria:~1. no endovascular repair of the femoropopliteal artery~2. endovascular or open re-intervention in the target limb~3. no pre-operative thin-section contrast-enhanced CTA of the target limb~4. no intraoperative angiogram or blood pressure measurements proximal and distal to the stent~5. aneurysmal disease of the target femoropopliteal artery~6. less than 2 patent crural outflow vessels~7. life expectancy ≤ 6 months~8. iodinated contrast allergy~9. orthopedic prosthesis in the region of interest~10. creatinine greater than 1.6 g/dL (unless dialysis patient, chronic dialysis patients are eligible)~11. inability to comply with 6-12-month contrast-enhanced CTA follow-up requirement~12. patient belongs to vulnerable population, i.e. pregnant women, prisoners, institutionalized individuals

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peripheral artery disease patients (Type: None): Patients with peripheral artery disease who were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have a stent in their femoropopliteal artery) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for 6-12 months. During the follow-up, a post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years old and above with urolithiasis scheduled for shock wave lithotripsy.~Exclusion Criteria:~* Contraindications to Flomax~* Patients with renal impairment (serum creatinine above 2.0)~* Patients with hepatic impairment (liver enzymes 2.5 times the upper limit of normal)~* Use of other oral alpha blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flomax (Type: EXPERIMENTAL): Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
- Sugar pill (Type: PLACEBO_COMPARATOR): Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues